522 related articles for article (PubMed ID: 31029796)
21. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.
Kirik D; Annett LE; Burger C; Muzyczka N; Mandel RJ; Björklund A
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2884-9. PubMed ID: 12601150
[TBL] [Abstract][Full Text] [Related]
22. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
[TBL] [Abstract][Full Text] [Related]
23. The Nigral Coup in Parkinson's Disease by α-Synuclein and Its Associated Rebels.
Sian-Hulsmann J; Riederer P
Cells; 2021 Mar; 10(3):. PubMed ID: 33803185
[TBL] [Abstract][Full Text] [Related]
24. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
25. Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of α-Synuclein in the Rat Brain.
Kelly R; Bemelmans AP; Joséphine C; Brouillet E; McKernan DP; Dowd E
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056822
[TBL] [Abstract][Full Text] [Related]
26. Gintonin Mitigates MPTP-Induced Loss of Nigrostriatal Dopaminergic Neurons and Accumulation of α-Synuclein via the Nrf2/HO-1 Pathway.
Jo MG; Ikram M; Jo MH; Yoo L; Chung KC; Nah SY; Hwang H; Rhim H; Kim MO
Mol Neurobiol; 2019 Jan; 56(1):39-55. PubMed ID: 29675576
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
28. α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.
Chu Y; Mickiewicz AL; Kordower JH
Neurobiol Dis; 2011 Jan; 41(1):71-82. PubMed ID: 20816781
[TBL] [Abstract][Full Text] [Related]
29. Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration.
Xilouri M; Brekk OR; Landeck N; Pitychoutis PM; Papasilekas T; Papadopoulou-Daifoti Z; Kirik D; Stefanis L
Brain; 2013 Jul; 136(Pt 7):2130-46. PubMed ID: 23757764
[TBL] [Abstract][Full Text] [Related]
30. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
31. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
[TBL] [Abstract][Full Text] [Related]
32. Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease.
Phan JA; Stokholm K; Zareba-Paslawska J; Jakobsen S; Vang K; Gjedde A; Landau AM; Romero-Ramos M
Sci Rep; 2017 Jul; 7(1):6363. PubMed ID: 28743955
[TBL] [Abstract][Full Text] [Related]
33. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
[TBL] [Abstract][Full Text] [Related]
34. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
[TBL] [Abstract][Full Text] [Related]
35. The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models.
Kelly R; Cairns AG; Ådén J; Almqvist F; Bemelmans AP; Brouillet E; Patton T; McKernan DP; Dowd E
Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827685
[TBL] [Abstract][Full Text] [Related]
36. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice.
Cai W; Feng D; Schwarzschild MA; McLean PJ; Chen X
EBioMedicine; 2018 Mar; 29():13-22. PubMed ID: 29433982
[TBL] [Abstract][Full Text] [Related]
37. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
Ulusoy A; Febbraro F; Jensen PH; Kirik D; Romero-Ramos M
Eur J Neurosci; 2010 Aug; 32(3):409-22. PubMed ID: 20704592
[TBL] [Abstract][Full Text] [Related]
38. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
39. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.
Gombash SE; Manfredsson FP; Kemp CJ; Kuhn NC; Fleming SM; Egan AE; Grant LM; Ciucci MR; MacKeigan JP; Sortwell CE
PLoS One; 2013; 8(11):e81426. PubMed ID: 24312298
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M
J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
